Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T20:30:56.052Z.
Calculation as of: 2026-10-06T20:30:56.052Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c0c25a561797b8251bbc96a681ec43d66f95a8f813bb62f19698de697ac6593e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$44.71M
EV/EBIT Ratio
82.66x
TTM Avg
44.61x
3Y Avg
49.72x
5Y Avg
49.72x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celularity Inc. (CELU) | $45.73M | N/A | N/A | N/A | N/A |
| Instil Bio, Inc. (TIL)vs › | $46.69M | N/A | N/A | N/A | N/A |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $44.72M | N/A | N/A | N/A | N/A |
| SANUWAVE Health Inc. (SNWV)vs › | $44.71M | 82.66x | 44.61x | 49.72x | 49.72x |
| DarioHealth Corp. (DRIO)vs › | $44.02M | N/A | 17.26x | 19.56x | 25.78x |
| Lite Strategy, Inc. (LITS)vs › | $47.98M | N/A | N/A | N/A | N/A |
| CVRx, Inc. (CVRX)vs › | $42.99M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $48.53M | N/A | N/A | N/A | N/A |
| Nano-X Imaging Ltd. (NNOX)vs › | $42.83M | N/A | N/A | N/A | N/A |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $42.72M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
